by Crestone, Inc. | Aug 15, 2022 | Press Releases
Announcement Regarding CRS0540: Crestone, Inc. and Praedicare Inc. Announce the Publication of Data on the Novel Antibiotic CRS0540 in the Hollow Fiber System Model of the Orphan Disease Disseminated Listeriosis August 15, 2022—End-to-end drug development company...
by Crestone, Inc. | Aug 4, 2022 | Information
What Causes C. difficile Infection? Every year, around 200,000 to half a million people in the United States become infected with C. difficile. However, the numbers have decreased in recent years because of increased prevention methods.C. difficile enters your body...
by Crestone, Inc. | Jul 29, 2022 | Information
Clostridium difficile infection (CDI) is a gastrointestinal condition caused by toxin-producing strains of C. difficile bacteria. Commonly referred to as C. diff infection, this illness is a result of an excess of the Clostridioides difficile bacterium (also referred...
by Crestone, Inc. | Jul 21, 2022 | Information
Clostridioides difficile is a bacterium that is found in the intestines of humans and animals and in the environment. Certain strains of this organism can produce toxins that cause damage to the colon of humans resulting in diarrhea known as C. difficile infection or...
by Crestone, Inc. | Jun 28, 2022 | Events
2022 ASM Microbe Presentation Details Oral Session: In vivo Pharmacodynamic Evaluation of CRS0540 in the Murine Thigh and Lung Infection Models against Staphylococcus aureus Poster: Potency of the Novel PolC DNA Polymerase Inhibitor CRS0540 in a Disseminated Listeria...
